Patents by Inventor Peter U. Park

Peter U. Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210301031
    Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: January 20, 2021
    Publication date: September 30, 2021
    Inventors: Donald A. BERGSTROM, Natalya D. BODYAK, Timothy B. LOWINGER, Peter U. PARK, Laura L. POLING, Aleksandr V. YURKOVETSKIY
  • Publication number: 20210101933
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Application
    Filed: October 26, 2020
    Publication date: April 8, 2021
    Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma MUDD, Peter U. PARK, Punit UPADHYAYA
  • Patent number: 10947317
    Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: March 16, 2021
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Donald A. Bergstrom, Natalya D. Bodyak, Timothy B. Lowinger, Peter U. Park, Laura L. Poling, Aleksandr V. Yurkovetskiy
  • Publication number: 20200408765
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 31, 2020
    Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
  • Patent number: 10875894
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 29, 2020
    Assignee: BicycleTx Limited
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter U. Park, Punit Upadhyaya
  • Publication number: 20200354406
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.
    Type: Application
    Filed: May 11, 2020
    Publication date: November 12, 2020
    Inventors: Tom Li STEPHEN, Kevin MCDONNELL, Nicholas KEEN, Liuhong CHEN, Helen HARRISON, Peter U. PARK, Michael SKYNNER, Harvey CHE
  • Publication number: 20200291096
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 14, 2018
    Publication date: September 17, 2020
    Inventors: Nicholas Keen, Kevin McDonnell, Peter U. Park
  • Publication number: 20200283482
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 14, 2018
    Publication date: September 10, 2020
    Inventors: Nicholas Keen, Kevin McDonnell, Peter U. Park, Gemma Elizabeth Mudd, Gabriela Ivanova-Berndt
  • Publication number: 20200270361
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 27, 2020
    Inventors: Jutta DECKERT, Julianto SETIADY, Peter U. PARK
  • Patent number: 10556958
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 11, 2020
    Assignee: Debiopharm International, S.A.
    Inventors: Jutta Deckert, Julianto Setiady, Peter U. Park
  • Publication number: 20200031941
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: October 2, 2019
    Publication date: January 30, 2020
    Inventors: Natalya D. BODYAK, Michael J. DeVIT, Eric M. KRAULAND, Timothy B. LOWINGER, Peter U. PARK, Bianka PRINZ, Aleksandr V. YURKOVETSKIY
  • Publication number: 20190263866
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 29, 2019
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter U. Park, Punit Upadhyaya
  • Publication number: 20180230218
    Abstract: MET is a receptor tyrosine kinase found on the surface of tumor cells. The present invention includes anti-MET antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
    Type: Application
    Filed: January 3, 2018
    Publication date: August 16, 2018
    Inventors: Thomas Chittenden, Jutta Deckert, Stuart William Hicks, Katharine C. Lai, Peter U. Park, Lingyun Rui, Daniel J. Tavares, Neeraj Kohli
  • Publication number: 20170343550
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic rnyelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma.
    Type: Application
    Filed: January 9, 2017
    Publication date: November 30, 2017
    Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
  • Patent number: 9808528
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders, such as cancer in a subject having low HER2 expression with the conjugates or their compositions are also described.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: November 7, 2017
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Natalya D. Bodyak, Timothy B. Lowinger, Peter U. Park, Aleksandr V. Yurkovetskiy
  • Publication number: 20170313778
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Inventors: Natalya D. BODYAK, Michael J. DeVIT, Eric M. KRAULAND, Timothy B. LOWINGER, Peter U. PARK, Bianka PRINZ, Aleksandr V. YURKOVETSKIY
  • Publication number: 20170266311
    Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 21, 2017
    Inventors: Donald A. BERGSTROM, Natalya D. BODYAK, Timothy B. LOWINGER, Peter U. PARK, Laura L. POLING, Aleksandr V. YURKOVETSKIY
  • Patent number: 9738720
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 22, 2017
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Natalya D. Bodyak, Michael J. DeVit, Eric M. Krauland, Timothy B. Lowinger, Peter U. Park, Bianka Prinz, Aleksandr V. Yurkovetskiy
  • Publication number: 20170066830
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 9, 2017
    Inventors: Natalya D. Bodyak, Michael J. DeVit, Eric M. Krauland, Timothy B. Lowinger, Peter U. Park, Bianka Prinz, Aleksandr V. Yurkovetskiy
  • Patent number: 9555112
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: January 31, 2017
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Natalya D. Bodyak, Michael J. DeVit, Eric M. Krauland, Timothy B. Lowinger, Peter U. Park, Bianka Prinz, Aleksandr V. Yurkovetskiy